吗替麦考酚酯用于幼年特发性炎症性肌病的应用经验
研究回顾性纳入英国幼年皮肌炎研究组和意大利热那亚Giannina Gaslini研究所的29例幼年特发性炎症性肌病患者,评估吗替麦考酚酯的疗效与安全性。治疗期间肌力、皮肤疾病活动和整体疾病活动指标均有改善,无活动性疾病患者比例从基线10.3%升至末次随访68.5%,糖皮质激素剂量显著降低,未报告相关副作用。作者认为吗替麦考酚酯是幼年特发性炎症性肌病的有价值治疗选择。
要点
- 29例幼年特发性炎症性肌病患者中23例为幼年皮肌炎、6例为重叠性肌炎。
- 治疗期间Manual Muscle Test-8正常评分频率从50.0%升至83.3%,无活动性疾病比例从10.3%升至68.5%。
- 糖皮质激素剂量从0.3 mg/kg/天显著降至0.1 mg/kg/天,未报告相关副作用。
核心结论
- 作者的经验提示吗替麦考酚酯是幼年特发性炎症性肌病管理中有价值的治疗选择。
研究设计与样本
- 回顾性收集英国幼年皮肌炎研究组和意大利热那亚Giannina Gaslini研究所诊断幼年特发性炎症性肌病并接受吗替麦考酚酯治疗的患者,共纳入29例。
- 在吗替麦考酚酯起始时、治疗开始后3、6、12个月及末次随访时收集临床表现、实验室数据、医师主观疾病活动评估、标准化肌力/耐力结局指标、皮肤疾病活动、躯体功能、整体疾病活动、累积损伤和正在进行的治疗。
主要发现
- 治疗期间肌力、皮肤疾病活动和整体疾病活动指标均见改善:Manual Muscle Test-8正常评分频率从50.0%升至83.3%,Childhood Myositis Activity Score从53.5%升至88.9%,DAS肌肉成分从55.2%升至84.2%,DAS皮肤成分从31.0%升至42.1%,皮肤疾病活动视觉模拟量表从25.0%升至47.4%,整体疾病活动视觉模拟量表从7.1%升至42.1%。
- 无活动性疾病患者比例从基线10.3%升至末次随访68.5%。
- 糖皮质激素剂量从0.3 mg/kg/天显著降至0.1 mg/kg/天。
- 未报告相关副作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to evaluate the efficacy and safety of MMF in juvenile idiopathic inflammatory myopathies (JIIMs). METHODS: Patients diagnosed with JIIM and treated with MMF enrolled in the Juvenile Dermatomyositis Research Group (JDRG) in the UK or followed at the Giannina Gaslini Institute in Genoa, Italy, were included. The following information was collected retrospectively at MMF initiation, at 3, 6 and 12 months after treatment start, and at last follow-up visit: clinical manifestations, laboratory data, physicians' subjective assessment of disease activity, standardized outcome measures of muscle strength/endurance, cutaneous disease activity, physical function, global disease activity, cumulative damage, and ongoing treatment. RESULTS: Of the 29 patients included, 23 had juvenile DM and 6 had overlap myositis. During administration of MMF, improvement in measures of muscle strength, skin disease activity, and overall disease activity was seen, with an increase in the frequency of normal scores for Manual Muscle Test-8 from 50.0% to 83.3%, Childhood Myositis Activity Score from 53.5% to 88.9%, muscle component of DAS from 55.2% to 84.2%, skin component of DAS from 31.0% to 42.1%, visual analogue scale for skin disease activity from 25.0% to 47.4%, and visual analogue scale for overall disease activity from 7.1% to 42.1%. The number of patients with inactive disease increased from 10.3% at baseline to 68.5% at last follow-up. CS dose was significantly reduced, from 0.3 to 0.1 mg/kg/day. No relevant side effects were reported. CONCLUSION: Our experience suggests that MMF is a valuable therapeutic option for the management of JIIM.
引用
- Varnier GC, Consolaro A, Cheng IL, et al. Experience with the use of mycophenolate mofetil in juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford). 2023. PMID: 35929784. doi:10.1093/rheumatology/keac404
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。